Infectious Disease Pharmacokinetics Lab

IDPL, run by Dr. Charles Peloquin, provides therapeutic drug monitoring for antimicrobials (antiTB, BLs, FQs, linezolid, antivirals, antifungals) using LCMSMS

[Infectious Disease Pharmacokinetics Lab @IDPLab]

Our updated drugs list. Also can be found on our webpage: https://t.co/NkLPfBoGCj

[Infectious Disease Pharmacokinetics Lab @IDPLab]

@erin_barreto @kjkpharm @Stevens_AK @UKAbxStew @SIDPharm @accpinfdprn @ABsteward @MayoPharmRes @CRE_RESPOND @ogi_gajic @MayoClinicINFD @accpcritprn @mtbastin If they haven’t come, we haven’t fully built it yet :-)

[Infectious Disease Pharmacokinetics Lab @IDPLab]

@FlorianLemaitr5 @BradSpellberg TB multiplies ervery 18-20 hours in vitro, and SA about every 30 minutes.

I would probably give 600 mg BID, since RIF is gone by about 12 hours, and if the companion drug is dosed several times per day, only some of the doses would have RIF present for “synergy.” C.Peloquin” 2/2

[Infectious Disease Pharmacokinetics Lab @IDPLab]

@FlorianLemaitr5 @BradSpellberg “I have not done a study with 300 mg BID.

I have studied 600-900-1200 mg QD.

RIF does have saturable efflux during absorption providing higher than proportional AUCs at higher doses.
You probably have seen that with the clinical service. 1/2

[Jim Rhodes @njrhodes_rx]

Wonderful collaboration of @mwupce with @NM_IDSteward on this case report and lit review of M. abscessus in CNS; early TDM of abx may help guide abx. H/t @IDPLab for PK.

https://t.co/Cc1BefGQkc
w/ En-Ling Wu @HeetiOmar @BrianHoff_ @KKruegerMD @jdubbs912 and Phillip Santoiemma

[Infectious Disease Pharmacokinetics Lab @IDPLab]

fT>4xMIC at 0-24hr of therapy was the top predictor of positive outcomes in ICU HAP/VAP
https://t.co/hFracwMNtP

[UF Pharmacy @UFPharmacy]

Scientists from @UFHealth and the @IDPLab recently used machine learning to retrospectively evaluate outcomes for more than 700 intensive care unit patients who were infected with hospital-acquired and ventilator-associated pneumonia. #AIatUF https://t.co/nr3JXOA2DC

[Infectious Disease Pharmacokinetics Lab @IDPLab]

#IDTwitter Impact of Beta-Lactam Early and Cumulative PK/PD Target Attainment in ICU pneumonias using machine learning: fT>4xMIC in the first 24hr was the top predictor of therapy outcomes, followed by fT>MIC for the remaining therapy duration
https://t.co/hFracwMNtP

[Infectious Disease Pharmacokinetics Lab @IDPLab]

@JGPharmD @njrhodes_rx @IdVilchez @jfsisaacs5 @OncIDPharmd @RazonableMD @JonathanRyderMD @mmPharmD @ErinMcCreary @ConanMacDougall @theIDPharmD @cmejiachew @DousaKhalid @DrDCNguyen @julie_justo @voRIC0nazole We usually start with 600 mg daily abd check 2hr, 6hr and trough (target <2). If trough is high may administer 3x wkly

[UF Pharmacy @UFPharmacy]

Scientists from @UFHealth and the @IDPLab recently used machine learning to retrospectively evaluate outcomes for more than 700 intensive care unit patients who were infected with hospital-acquired and ventilator-associated pneumonia. #AIatUF https://t.co/nr3JXOA2DC

[Contagion @Contagion_Live]

At #MADID2022 Dr. Mohammad Alshaer @IDPLab sat down to discuss his study that looked at the utilization of the technology with this #antibiotic class in hospital-acquired pneumonia and ventilator-associated pneumonia.

https://t.co/wSCu3gG8HW

[Infectious Disease Pharmacokinetics Lab @IDPLab]

@wfwrighID Many clinicians fear cefepime because of ill-defined “neurotoxicity” which can be caused by many things esp in icu setting

[Infectious Disease Pharmacokinetics Lab @IDPLab]

See you soon at @MAD_ID_ASP
This year, we all will be there!

[MAD-ID The Antimicrobial Stewardship Meeting®️ @MAD_ID_ASP]

💥Registration is open for #MADID2022! The 24th Annual MAD-ID Meeting, The Antimicrobial Stewardship Meeting® will take place May 18-21, 2022 at the Hyatt Regency Orlando, FL. For more info visit https://t.co/hYbKODeW3w We hope to see you there! #IDTwitter

[Intensive Care Medicine @yourICM]

TARGET trial results? Let's discuss about
🛋️ SOFA score & its changes
💉piperacillin concentrations in both arms
💉daily dose/dose adjustments
🧫 microbiologic cultures findings
@IDPLab https://t.co/wNN7qXz5ZQ

Authors' reply https://t.co/16oXw093ax

& RCT https://t.co/mOSOrGkSfx

[Infectious Disease Pharmacokinetics Lab @IDPLab]

..couldn't find in the paper the N of RRT patients, esp that the authors allowed inclusion of RRT pts after protocol modification in 2017.

7) Again, great work @hagel_stefan @jasonroberts_pk and thanks for paving the way for more TDM work in the future!

Good night!

[Infectious Disease Pharmacokinetics Lab @IDPLab]

#IDtwitter TARGET Trial is such a great work by @hagel_stefan @jasonroberts_pk Some take-home messages will follow.
A disclosure before we move on, this is NOT Dr. Peloquin's account but rather his lab's which handled by different people. Tonight, Mo Alshaer will be your host!

[Erin Barreto @erin_barreto]

1/?
Taking some time to read TARGET (https://t.co/cNy7ZFn988) I finally have some thoughts, sorry wasn't prepared for the rapid fire commentary of the last couple of days, i'm ready now! See 🧵

1) I like this trial and I think @hagel_stefan @jasonroberts_pk and the team...

[Infectious Disease Pharmacokinetics Lab @IDPLab]

..these were secondary analyses, and would like the clinicians not to misunderstand this as TDM has no role here.
6) Authors found difference in mortality in pts with pip conc >96 mg/L. These might be RRT patients (RRT might be an independent predictor of mortality). I